MHCombiotic
MHCombiotic (MHC) is a preclinical biotech company based in Calgary, Canada, dedicated to combating antimicrobial resistance (AMR) through the development of innovative antimicrobial solutions known as Combiotics™. The company focuses on safe antimicrobial discovery with a low chance of future resistance, utilizing a synergistic combination of plant-based small molecules and inorganic salts. MHC collaborates with top global research institutes and industries to advance its state-of-the-art technology, aiming to provide efficacious and cost-effective solutions to global health challenges.
Industries
Nr. of Employees
small (1-50)
Products
Antimicrobial hydrogel wound dressing and irrigation formulation
Hydrated barrier hydrogel and complementary irrigation solution formulated to maintain wound moisture, support cleansing, reduce dressing-change trauma, and limit microbial growth within dressings.
Inhaled antimicrobial and anti-inflammatory therapeutic candidate for respiratory infections
Therapeutic approach intended to provide broad-spectrum antimicrobial and anti-inflammatory activity for respiratory infections, including antibiofilm and antioxidant effects to support lung health.
Systemic antimicrobial therapeutic candidate for sepsis
Therapeutic candidate aimed at addressing systemic infections and sepsis by combining broad-spectrum antimicrobial activity with modulation of inflammation and oxidative stress.
Antimicrobial hydrogel wound dressing and irrigation formulation
Hydrated barrier hydrogel and complementary irrigation solution formulated to maintain wound moisture, support cleansing, reduce dressing-change trauma, and limit microbial growth within dressings.
Inhaled antimicrobial and anti-inflammatory therapeutic candidate for respiratory infections
Therapeutic approach intended to provide broad-spectrum antimicrobial and anti-inflammatory activity for respiratory infections, including antibiofilm and antioxidant effects to support lung health.
Systemic antimicrobial therapeutic candidate for sepsis
Therapeutic candidate aimed at addressing systemic infections and sepsis by combining broad-spectrum antimicrobial activity with modulation of inflammation and oxidative stress.
Expertise Areas
- Antimicrobial discovery and preclinical development
- Biofilm disruption and antibiofilm strategies
- Wound care device formulation
- Respiratory and systemic infection therapeutics
Key Technologies
- Multi-omics analysis
- Probe-based biochemical assays
- High-throughput formulation screening
- Hydrated hydrogel wound dressings
Key People
News & Updates
Awarded for pioneering innovative technology in antimicrobial research.
Recognition for significant contributions to antimicrobial research and innovation.
Awarded for pioneering innovative technology in life sciences.
Awarded for pioneering innovative technology in antimicrobial research.
Recognition for significant contributions to antimicrobial research and innovation.
Awarded for pioneering innovative technology in life sciences.